S.09.03 Long acting naltrexone implants for heroin dependence

Krupitsky, Evgeny; Zvartau, E.; Woody, G.

doi:10.1016/s0924-977x(09)70234-2

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The final group of patients ( n =306) has completed treatment, and outcome data are not yet available. However, we completed an interim analysis of 190 patients in December 2008 [15]. …”

Section: Studies With Long-acting Sustained-release Formulationsmentioning

confidence: 99%

See 1 more Smart Citation

Use of Naltrexone to Treat Opioid Addiction in a Country in Which Methadone and Buprenorphine Are Not Available

Krupitsky

Zvartau

Woody

2010

Curr Psychiatry Rep

View full text Add to dashboard Cite

Opioid dependence is one of the most severe drug dependencies. Naltrexone is a medication that completely blocks the subjective and other effects of opioids and, when administered to detoxified opioid addicts and taken as directed, prevents relapse and helps maintain abstinence. The major problem with naltrexone is poor compliance, particularly in countries in which there is a treatment alternative based on substitution of illicit opioids such as heroin with orally administered opioid agonists (methadone) or partial agonist/antagonists (buprenorphine). In Russia, substitution therapy is forbidden by law, and naltrexone is the only available pharmacotherapy for heroin dependence. Due to the lack of alternatives to naltrexone and stronger family control of compliance (adherence), naltrexone is more effective for relapse prevention and abstinence stabilization in Russia than in Western countries. Long-acting, sustained-release formulations (injectable and implantable) seem particularly effective compared with oral formulations. This article summarizes the results of studies conducted in Russia during the past 10 years that demonstrate these points.

show abstract

“…The final group of patients ( n =306) has completed treatment, and outcome data are not yet available. However, we completed an interim analysis of 190 patients in December 2008 [15]. …”

Section: Studies With Long-acting Sustained-release Formulationsmentioning

confidence: 99%

“…In summary, the Russian long-acting, sustained-release naltrexone implant (Prodetoxon) appears to be safe and more effective than the oral naltrexone and placebo implant for prevention of relapse to heroin dependence [15]. The blockade provided by Prodetoxon is very difficult to override.…”

Section: Studies With Long-acting Sustained-release Formulationsmentioning

confidence: 99%